SI9420079A - Thrombopoietin. - Google Patents

Thrombopoietin. Download PDF

Info

Publication number: SI9420079A
Authority: SI; Slovenia
Prior art keywords: mpl; ugandan; dna; sequence; ligand
Prior art date: 1994-01-03

Application number

SI9420079A

Other languages

English (en)

Slovenian (sl)

Inventor

Dan L Eaton

Sauvage Frederic J De

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-03

Filing date

1994-12-28

Publication date

1997-02-28

1994-02-15 Priority claimed from US08/196,689 external-priority patent/US8357513B1/en

1994-05-25 Priority claimed from US08/249,376 external-priority patent/US8192955B1/en

1994-12-02 Priority claimed from US08/348,657 external-priority patent/US6660256B1/en

1994-12-28 Application filed by Genentech Inc filed Critical Genentech Inc

1997-02-28 Publication of SI9420079A publication Critical patent/SI9420079A/sl

Links

108010041111 Thrombopoietin Proteins 0.000 title claims abstract description 409
102000036693 Thrombopoietin Human genes 0.000 title claims abstract description 406
210000004027 cell Anatomy 0.000 claims description 195
108020004414 DNA Proteins 0.000 claims description 176
238000000034 method Methods 0.000 claims description 143
108090000623 proteins and genes Proteins 0.000 claims description 140
241000282414 Homo sapiens Species 0.000 claims description 138
108090000765 processed proteins & peptides Proteins 0.000 claims description 88
102000004196 processed proteins & peptides Human genes 0.000 claims description 81
229920001184 polypeptide Polymers 0.000 claims description 79
150000007523 nucleic acids Chemical class 0.000 claims description 76
102000039446 nucleic acids Human genes 0.000 claims description 66
108020004707 nucleic acids Proteins 0.000 claims description 66
239000013598 vector Substances 0.000 claims description 63
239000002299 complementary DNA Substances 0.000 claims description 54
125000003729 nucleotide group Chemical group 0.000 claims description 52
239000003446 ligand Substances 0.000 claims description 51
239000002773 nucleotide Substances 0.000 claims description 51
230000027455 binding Effects 0.000 claims description 50
230000014509 gene expression Effects 0.000 claims description 48
230000008569 process Effects 0.000 claims description 45
108010002386 Interleukin-3 Proteins 0.000 claims description 35
108091034117 Oligonucleotide Proteins 0.000 claims description 32
238000012360 testing method Methods 0.000 claims description 32
238000002360 preparation method Methods 0.000 claims description 29
230000004071 biological effect Effects 0.000 claims description 28
238000004519 manufacturing process Methods 0.000 claims description 28
-1 Epo Proteins 0.000 claims description 27
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 25
239000003795 chemical substances by application Substances 0.000 claims description 25
239000013604 expression vector Substances 0.000 claims description 25
108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
102000004127 Cytokines Human genes 0.000 claims description 23
108090000695 Cytokines Proteins 0.000 claims description 23
238000000746 purification Methods 0.000 claims description 22
108091026890 Coding region Proteins 0.000 claims description 21
230000004927 fusion Effects 0.000 claims description 21
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 20
238000006243 chemical reaction Methods 0.000 claims description 20
238000003780 insertion Methods 0.000 claims description 20
230000037431 insertion Effects 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 20
238000010348 incorporation Methods 0.000 claims description 17
230000004936 stimulating effect Effects 0.000 claims description 17
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 16
239000002609 medium Substances 0.000 claims description 15
229940104230 thymidine Drugs 0.000 claims description 14
238000013518 transcription Methods 0.000 claims description 14
230000035897 transcription Effects 0.000 claims description 14
239000004202 carbamide Substances 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 13
210000004408 hybridoma Anatomy 0.000 claims description 13
238000001890 transfection Methods 0.000 claims description 13
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 12
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 12
102000003886 Glycoproteins Human genes 0.000 claims description 11
108090000288 Glycoproteins Proteins 0.000 claims description 11
108090001005 Interleukin-6 Proteins 0.000 claims description 11
102000004889 Interleukin-6 Human genes 0.000 claims description 11
239000001963 growth medium Substances 0.000 claims description 11
210000004962 mammalian cell Anatomy 0.000 claims description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
102000015696 Interleukins Human genes 0.000 claims description 9
108010063738 Interleukins Proteins 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 9
238000002955 isolation Methods 0.000 claims description 9
230000001419 dependent effect Effects 0.000 claims description 8
230000002103 transcriptional effect Effects 0.000 claims description 8
102000000589 Interleukin-1 Human genes 0.000 claims description 7
108010002352 Interleukin-1 Proteins 0.000 claims description 7
210000003734 kidney Anatomy 0.000 claims description 7
229940047122 interleukins Drugs 0.000 claims description 6
108010002335 Interleukin-9 Proteins 0.000 claims description 5
238000001042 affinity chromatography Methods 0.000 claims description 5
238000004587 chromatography analysis Methods 0.000 claims description 5
238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 5
108020004999 messenger RNA Proteins 0.000 claims description 5
108700028369 Alleles Proteins 0.000 claims description 4
108010002350 Interleukin-2 Proteins 0.000 claims description 4
102000000588 Interleukin-2 Human genes 0.000 claims description 4
108010002616 Interleukin-5 Proteins 0.000 claims description 4
108700024394 Exon Proteins 0.000 claims description 3
108010002586 Interleukin-7 Proteins 0.000 claims description 3
108090001007 Interleukin-8 Proteins 0.000 claims description 3
230000000977 initiatory effect Effects 0.000 claims description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
102000000585 Interleukin-9 Human genes 0.000 claims description 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000002068 genetic effect Effects 0.000 claims description 2
238000011330 nucleic acid test Methods 0.000 claims 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
108090000177 Interleukin-11 Proteins 0.000 claims 1
102100032352 Leukemia inhibitory factor Human genes 0.000 claims 1
108090000581 Leukemia inhibitory factor Proteins 0.000 claims 1
239000006143 cell culture medium Substances 0.000 claims 1
210000003593 megakaryocyte Anatomy 0.000 abstract description 43
206010043554 thrombocytopenia Diseases 0.000 abstract description 43
230000035800 maturation Effects 0.000 abstract description 25
238000011282 treatment Methods 0.000 abstract description 21
230000004069 differentiation Effects 0.000 abstract description 17
150000001875 compounds Chemical class 0.000 abstract description 13
210000000601 blood cell Anatomy 0.000 abstract description 12
230000010076 replication Effects 0.000 abstract description 11
210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 abstract description 5
238000010188 recombinant method Methods 0.000 abstract description 2
238000010189 synthetic method Methods 0.000 abstract description 2
101150001753 MPL gene Proteins 0.000 description 243
235000018102 proteins Nutrition 0.000 description 97
102000004169 proteins and genes Human genes 0.000 description 97
210000001772 blood platelet Anatomy 0.000 description 93
239000012634 fragment Substances 0.000 description 88
125000003275 alpha amino acid group Chemical group 0.000 description 79
230000000694 effects Effects 0.000 description 78
235000001014 amino acid Nutrition 0.000 description 53
239000013612 plasmid Substances 0.000 description 53
229940024606 amino acid Drugs 0.000 description 48
150000001413 amino acids Chemical class 0.000 description 48
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 42
238000003752 polymerase chain reaction Methods 0.000 description 41
241001529936 Murinae Species 0.000 description 40
210000004369 blood Anatomy 0.000 description 40
239000008280 blood Substances 0.000 description 40
102000003951 Erythropoietin Human genes 0.000 description 37
108090000394 Erythropoietin Proteins 0.000 description 37
238000012217 deletion Methods 0.000 description 37
230000037430 deletion Effects 0.000 description 37
125000000539 amino acid group Chemical group 0.000 description 36
229940105423 erythropoietin Drugs 0.000 description 36
241000699670 Mus sp. Species 0.000 description 33
102100039064 Interleukin-3 Human genes 0.000 description 32
239000000872 buffer Substances 0.000 description 32
210000002381 plasma Anatomy 0.000 description 32
229940076264 interleukin-3 Drugs 0.000 description 30
241000894007 species Species 0.000 description 30
238000006467 substitution reaction Methods 0.000 description 30
101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 29
230000015572 biosynthetic process Effects 0.000 description 29
102000005962 receptors Human genes 0.000 description 29
108020003175 receptors Proteins 0.000 description 29
239000000523 sample Substances 0.000 description 29
229920002684 Sepharose Polymers 0.000 description 27
230000035755 proliferation Effects 0.000 description 26
108060003951 Immunoglobulin Proteins 0.000 description 24
108010076504 Protein Sorting Signals Proteins 0.000 description 24
239000000427 antigen Substances 0.000 description 24
108091007433 antigens Proteins 0.000 description 24
102000036639 antigens Human genes 0.000 description 24
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 24
102000018358 immunoglobulin Human genes 0.000 description 24
230000035772 mutation Effects 0.000 description 24
241000699666 Mus <mouse, genus> Species 0.000 description 23
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 23
239000000126 substance Substances 0.000 description 23
108010029485 Protein Isoforms Proteins 0.000 description 22
102000001708 Protein Isoforms Human genes 0.000 description 22
240000004808 Saccharomyces cerevisiae Species 0.000 description 22
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 22
239000000499 gel Substances 0.000 description 22
238000000338 in vitro Methods 0.000 description 22
239000013615 primer Substances 0.000 description 22
238000004113 cell culture Methods 0.000 description 20
238000001727 in vivo Methods 0.000 description 20
241000588724 Escherichia coli Species 0.000 description 19
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 19
230000003394 haemopoietic effect Effects 0.000 description 18
238000004153 renaturation Methods 0.000 description 18
241000282898 Sus scrofa Species 0.000 description 17
210000004899 c-terminal region Anatomy 0.000 description 17
210000004978 chinese hamster ovary cell Anatomy 0.000 description 17
230000006870 function Effects 0.000 description 17
108091008146 restriction endonucleases Proteins 0.000 description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
238000003776 cleavage reaction Methods 0.000 description 16
230000012010 growth Effects 0.000 description 16
238000002703 mutagenesis Methods 0.000 description 16
231100000350 mutagenesis Toxicity 0.000 description 16
230000007017 scission Effects 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 15
230000001965 increasing effect Effects 0.000 description 15
210000002966 serum Anatomy 0.000 description 15
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 14
230000004988 N-glycosylation Effects 0.000 description 14
238000004458 analytical method Methods 0.000 description 14
235000018417 cysteine Nutrition 0.000 description 14
102000003675 cytokine receptors Human genes 0.000 description 14
108010057085 cytokine receptors Proteins 0.000 description 14
230000013595 glycosylation Effects 0.000 description 14
238000006206 glycosylation reaction Methods 0.000 description 14
230000004048 modification Effects 0.000 description 14
238000012986 modification Methods 0.000 description 14
210000000130 stem cell Anatomy 0.000 description 14
102000004190 Enzymes Human genes 0.000 description 13
108090000790 Enzymes Proteins 0.000 description 13
241001465754 Metazoa Species 0.000 description 13
230000029087 digestion Effects 0.000 description 13
229940088598 enzyme Drugs 0.000 description 13
239000003102 growth factor Substances 0.000 description 13
230000002829 reductive effect Effects 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 12
230000000295 complement effect Effects 0.000 description 12
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
229940079593 drug Drugs 0.000 description 12
102000044890 human EPO Human genes 0.000 description 12
210000004185 liver Anatomy 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 12
239000002243 precursor Substances 0.000 description 12
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 11
210000003743 erythrocyte Anatomy 0.000 description 11
229960003180 glutathione Drugs 0.000 description 11
230000001361 thrombopoietic effect Effects 0.000 description 11
108010047041 Complementarity Determining Regions Proteins 0.000 description 10
241000196324 Embryophyta Species 0.000 description 10
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 10
101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
238000003556 assay Methods 0.000 description 10
210000001185 bone marrow Anatomy 0.000 description 10
239000003638 chemical reducing agent Substances 0.000 description 10
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 10
102000053400 human TPO Human genes 0.000 description 10
229940072221 immunoglobulins Drugs 0.000 description 10
239000000543 intermediate Substances 0.000 description 10
210000003292 kidney cell Anatomy 0.000 description 10
239000012528 membrane Substances 0.000 description 10
230000002062 proliferating effect Effects 0.000 description 10
238000011084 recovery Methods 0.000 description 10
230000001105 regulatory effect Effects 0.000 description 10
230000000638 stimulation Effects 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
108020004705 Codon Proteins 0.000 description 9
108010071942 Colony-Stimulating Factors Proteins 0.000 description 9
108010053070 Glutathione Disulfide Proteins 0.000 description 9
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 9
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 9
206010035226 Plasma cell myeloma Diseases 0.000 description 9
150000001720 carbohydrates Chemical group 0.000 description 9
238000011161 development Methods 0.000 description 9
230000018109 developmental process Effects 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
239000012636 effector Substances 0.000 description 9
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 9
210000003958 hematopoietic stem cell Anatomy 0.000 description 9
201000000050 myeloid neoplasm Diseases 0.000 description 9
239000006176 redox buffer Substances 0.000 description 9
238000010561 standard procedure Methods 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
108090001090 Lectins Proteins 0.000 description 8
102000004856 Lectins Human genes 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
108700026244 Open Reading Frames Proteins 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 8
238000010367 cloning Methods 0.000 description 8
239000003636 conditioned culture medium Substances 0.000 description 8
230000001086 cytosolic effect Effects 0.000 description 8
230000002354 daily effect Effects 0.000 description 8
230000006378 damage Effects 0.000 description 8
230000001605 fetal effect Effects 0.000 description 8
239000002523 lectin Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical class COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 7
238000002965 ELISA Methods 0.000 description 7
102100020880 Kit ligand Human genes 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 7
108010039445 Stem Cell Factor Proteins 0.000 description 7
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
230000008859 change Effects 0.000 description 7
230000003196 chaotropic effect Effects 0.000 description 7
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
230000002255 enzymatic effect Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000003862 glucocorticoid Substances 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
230000001900 immune effect Effects 0.000 description 7
230000006698 induction Effects 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
244000005700 microbiome Species 0.000 description 7
239000007800 oxidant agent Substances 0.000 description 7
239000008188 pellet Substances 0.000 description 7
239000012071 phase Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
230000017854 proteolysis Effects 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
230000035921 thrombopoiesis Effects 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
108010024636 Glutathione Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
241000282412 Homo Species 0.000 description 6
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
229930193140 Neomycin Natural products 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
241000251539 Vertebrata <Metazoa> Species 0.000 description 6
241000700605 Viruses Species 0.000 description 6
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
230000004663 cell proliferation Effects 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
229940088597 hormone Drugs 0.000 description 6
239000005556 hormone Substances 0.000 description 6
238000011534 incubation Methods 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
239000003550 marker Substances 0.000 description 6
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 6
229960004927 neomycin Drugs 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
230000028327 secretion Effects 0.000 description 6
238000000926 separation method Methods 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
102000007644 Colony-Stimulating Factors Human genes 0.000 description 5
102000053602 DNA Human genes 0.000 description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
102000035195 Peptidases Human genes 0.000 description 5
108091005804 Peptidases Proteins 0.000 description 5
239000004365 Protease Substances 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000007792 addition Methods 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000001332 colony forming effect Effects 0.000 description 5
229940047120 colony stimulating factors Drugs 0.000 description 5
238000010276 construction Methods 0.000 description 5
210000003714 granulocyte Anatomy 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
238000002372 labelling Methods 0.000 description 5
230000003343 megakaryocytopoietic effect Effects 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
210000001778 pluripotent stem cell Anatomy 0.000 description 5
229920002401 polyacrylamide Polymers 0.000 description 5
239000011347 resin Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
230000004044 response Effects 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
238000010911 splenectomy Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
230000009466 transformation Effects 0.000 description 5
230000010474 transient expression Effects 0.000 description 5
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 4
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
230000004544 DNA amplification Effects 0.000 description 4
102100031780 Endonuclease Human genes 0.000 description 4
108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 4
102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 4
208000031886 HIV Infections Diseases 0.000 description 4
208000037357 HIV infectious disease Diseases 0.000 description 4
108091027305 Heteroduplex Proteins 0.000 description 4
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
241000282887 Suidae Species 0.000 description 4
108091036066 Three prime untranslated region Proteins 0.000 description 4
208000005485 Thrombocytosis Diseases 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000000556 agonist Substances 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
238000004820 blood count Methods 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
238000001516 cell proliferation assay Methods 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
238000004132 cross linking Methods 0.000 description 4
238000012258 culturing Methods 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
239000003599 detergent Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 4
150000002019 disulfides Chemical class 0.000 description 4
238000010828 elution Methods 0.000 description 4
230000002349 favourable effect Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
201000004108 hypersplenism Diseases 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
210000005074 megakaryoblast Anatomy 0.000 description 4
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
229910052753 mercury Inorganic materials 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
230000001590 oxidative effect Effects 0.000 description 4
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
235000019419 proteases Nutrition 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000001509 sodium citrate Substances 0.000 description 4
238000005063 solubilization Methods 0.000 description 4
230000007928 solubilization Effects 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
238000010186 staining Methods 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
230000003582 thrombocytopenic effect Effects 0.000 description 4
230000002463 transducing effect Effects 0.000 description 4
238000000108 ultra-filtration Methods 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
238000005406 washing Methods 0.000 description 4
GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
241000589155 Agrobacterium tumefaciens Species 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
108091035707 Consensus sequence Proteins 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
102000004594 DNA Polymerase I Human genes 0.000 description 3
108010075944 Erythropoietin Receptors Proteins 0.000 description 3
102100036509 Erythropoietin receptor Human genes 0.000 description 3
241000233866 Fungi Species 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
208000028622 Immune thrombocytopenia Diseases 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
102000004388 Interleukin-4 Human genes 0.000 description 3
108090000978 Interleukin-4 Proteins 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
VXOKDLACQICQFA-UHFFFAOYSA-N N-Desethylamiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCNCC)C(I)=C1 VXOKDLACQICQFA-UHFFFAOYSA-N 0.000 description 3
125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
102000004140 Oncostatin M Human genes 0.000 description 3
108090000630 Oncostatin M Proteins 0.000 description 3
241000276498 Pollachius virens Species 0.000 description 3
108091036407 Polyadenylation Proteins 0.000 description 3
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
108020004682 Single-Stranded DNA Proteins 0.000 description 3
206010041660 Splenomegaly Diseases 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
101150077103 TPO gene Proteins 0.000 description 3
239000004473 Threonine Substances 0.000 description 3
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
102100034195 Thrombopoietin Human genes 0.000 description 3
102000006601 Thymidine Kinase Human genes 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000006978 adaptation Effects 0.000 description 3
239000012491 analyte Substances 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000001588 bifunctional effect Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
230000002759 chromosomal effect Effects 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
230000005757 colony formation Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000003431 cross linking reagent Substances 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
239000005547 deoxyribonucleotide Substances 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000001976 enzyme digestion Methods 0.000 description 3
210000003979 eosinophil Anatomy 0.000 description 3
230000000925 erythroid effect Effects 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
238000001641 gel filtration chromatography Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
239000000122 growth hormone Substances 0.000 description 3
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
210000000777 hematopoietic system Anatomy 0.000 description 3
208000018706 hematopoietic system disease Diseases 0.000 description 3
210000003630 histaminocyte Anatomy 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000011532 immunohistochemical staining Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
230000003993 interaction Effects 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000006166 lysate Substances 0.000 description 3
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
210000000066 myeloid cell Anatomy 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
238000007745 plasma electrolytic oxidation reaction Methods 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
238000001742 protein purification Methods 0.000 description 3
230000006337 proteolytic cleavage Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000035939 shock Effects 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000004332 silver Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical class [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
230000014616 translation Effects 0.000 description 3
230000014621 translational initiation Effects 0.000 description 3
239000001226 triphosphate Substances 0.000 description 3
235000011178 triphosphate Nutrition 0.000 description 3
108010087967 type I signal peptidase Proteins 0.000 description 3
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
229960002555 zidovudine Drugs 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
102000013563 Acid Phosphatase Human genes 0.000 description 2
108010051457 Acid Phosphatase Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
101710154825 Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
241000193830 Bacillus <bacterium> Species 0.000 description 2
206010065553 Bone marrow failure Diseases 0.000 description 2
241000701822 Bovine papillomavirus Species 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
230000009946 DNA mutation Effects 0.000 description 2
QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
108090000204 Dipeptidase 1 Proteins 0.000 description 2
241000255925 Diptera Species 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
206010018691 Granuloma Diseases 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
102000018997 Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
102000007072 Nerve Growth Factors Human genes 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
101710160107 Outer membrane protein A Proteins 0.000 description 2
108090000445 Parathyroid hormone Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
208000000474 Poliomyelitis Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
102100024952 Protein CBFA2T1 Human genes 0.000 description 2
101710127913 Proteoglycan 4 Proteins 0.000 description 2
RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108020005091 Replication Origin Proteins 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
241000256251 Spodoptera frugiperda Species 0.000 description 2
239000012505 Superdex™ Substances 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
102000011923 Thyrotropin Human genes 0.000 description 2
108010061174 Thyrotropin Proteins 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000005273 aeration Methods 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000000504 antifibrinolytic agent Substances 0.000 description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
210000003651 basophil Anatomy 0.000 description 2
230000008901 benefit Effects 0.000 description 2
102000006635 beta-lactamase Human genes 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000006287 biotinylation Effects 0.000 description 2
238000007413 biotinylation Methods 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
239000012930 cell culture fluid Substances 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
230000004087 circulation Effects 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
UFULAYFCSOUIOV-UHFFFAOYSA-O cysteaminium Chemical compound [NH3+]CCS UFULAYFCSOUIOV-UHFFFAOYSA-O 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
230000030609 dephosphorylation Effects 0.000 description 2
238000006209 dephosphorylation reaction Methods 0.000 description 2
229960000633 dextran sulfate Drugs 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
210000003013 erythroid precursor cell Anatomy 0.000 description 2
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
239000007789 gas Substances 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
239000012561 harvest cell culture fluid Substances 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
150000002463 imidates Chemical class 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000001788 irregular Effects 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229960003151 mercaptamine Drugs 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
230000000394 mitotic effect Effects 0.000 description 2
210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
229960000951 mycophenolic acid Drugs 0.000 description 2
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
108091027963 non-coding RNA Proteins 0.000 description 2
102000042567 non-coding RNA Human genes 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
229940046166 oligodeoxynucleotide Drugs 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229940043515 other immunoglobulins in atc Drugs 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
229960005205 prednisolone Drugs 0.000 description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
238000012545 processing Methods 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000009919 sequestration Effects 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
230000003381 solubilizing effect Effects 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
229920002397 thermoplastic olefin Polymers 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
230000003022 thrombocytopoietic effect Effects 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000012549 training Methods 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000000844 transformation Methods 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 description 1
BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
RQKYYWBMXHYBAP-UHFFFAOYSA-N 4-(chloromethyl)-2,2-dimethyl-1,3,2-dioxasilolane Chemical compound C[Si]1(C)OCC(CCl)O1 RQKYYWBMXHYBAP-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
VOROEQBFPPIACJ-UHFFFAOYSA-N 5-Phosphononorvaline Chemical compound OC(=O)C(N)CCCP(O)(O)=O VOROEQBFPPIACJ-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
241000256118 Aedes aegypti Species 0.000 description 1
241000256173 Aedes albopictus Species 0.000 description 1
VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
206010002961 Aplasia Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
241000272473 Aquila chrysaetos Species 0.000 description 1
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
241000351920 Aspergillus nidulans Species 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000713842 Avian sarcoma virus Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
108700019908 BL 11 Proteins 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
108700003860 Bacterial Genes Proteins 0.000 description 1
241000255791 Bombyx Species 0.000 description 1
241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
108091067901 CHAPS family Proteins 0.000 description 1
101100069857 Caenorhabditis elegans hil-4 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
108010041308 Endothelial Growth Factors Proteins 0.000 description 1
241000702224 Enterobacteria phage M13 Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
102100031939 Erythropoietin Human genes 0.000 description 1
241001522878 Escherichia coli B Species 0.000 description 1
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
241000272184 Falconiformes Species 0.000 description 1
208000026019 Fanconi renotubular syndrome Diseases 0.000 description 1
201000006328 Fanconi syndrome Diseases 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
206010016880 Folate deficiency Diseases 0.000 description 1
108010058643 Fungal Proteins Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
108010031186 Glycoside Hydrolases Proteins 0.000 description 1
102000005744 Glycoside Hydrolases Human genes 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
241000219146 Gossypium Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
108010004250 Inhibins Proteins 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102100025947 Insulin-like growth factor II Human genes 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
102000010786 Interleukin-5 Receptors Human genes 0.000 description 1
108010038484 Interleukin-5 Receptors Proteins 0.000 description 1
102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
241000235649 Kluyveromyces Species 0.000 description 1
244000285963 Kluyveromyces fragilis Species 0.000 description 1
241001138401 Kluyveromyces lactis Species 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical group NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
241000481961 Lachancea thermotolerans Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001306975 Liparis tunicatus Species 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
206010061298 Mucosal haemorrhage Diseases 0.000 description 1
101000799460 Mus musculus Thrombopoietin Proteins 0.000 description 1
VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
241000221960 Neurospora Species 0.000 description 1
241000221961 Neurospora crassa Species 0.000 description 1
101100190845 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pmp-1 gene Proteins 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
102100036893 Parathyroid hormone Human genes 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
241000228143 Penicillium Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
240000007377 Petunia x hybrida Species 0.000 description 1
102000001105 Phosphofructokinases Human genes 0.000 description 1
108010069341 Phosphofructokinases Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108010003044 Placental Lactogen Proteins 0.000 description 1
239000000381 Placental Lactogen Substances 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010033737 Pokeweed Mitogens Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
SVXXJYJCRNKDDE-AVGNSLFASA-N Pro-Pro-His Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CN=CN1 SVXXJYJCRNKDDE-AVGNSLFASA-N 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
102100024819 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
108010002519 Prolactin Receptors Proteins 0.000 description 1
102100029000 Prolactin receptor Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
102000004879 Racemases and epimerases Human genes 0.000 description 1
108090001066 Racemases and epimerases Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108090000103 Relaxin Proteins 0.000 description 1
102000003743 Relaxin Human genes 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
241000607720 Serratia Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
240000003768 Solanum lycopersicum Species 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
108700034501 Staphylococcus aureus auR Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
241000589500 Thermus aquaticus Species 0.000 description 1
COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
101710113649 Thyroid peroxidase Proteins 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
241001149964 Tolypocladium Species 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
206010053476 Traumatic haemorrhage Diseases 0.000 description 1
241000223259 Trichoderma Species 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
244000000188 Vaccinium ovalifolium Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
241000235013 Yarrowia Species 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
BHATUINFZWUDIX-UHFFFAOYSA-N Zwittergent 3-14 Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O BHATUINFZWUDIX-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000488 activin Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000008484 agonism Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
102000013529 alpha-Fetoproteins Human genes 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000868 anti-mullerian hormone Substances 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
238000011091 antibody purification Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
238000003491 array Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
229960000603 cefalotin Drugs 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000023715 cellular developmental process Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
230000007073 chemical hydrolysis Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
108700010039 chimeric receptor Proteins 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
VIMWCINSBRXAQH-UHFFFAOYSA-M chloro-(2-hydroxy-5-nitrophenyl)mercury Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[Hg]Cl VIMWCINSBRXAQH-UHFFFAOYSA-M 0.000 description 1
VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
229940106681 chloroacetic acid Drugs 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
238000011098 chromatofocusing Methods 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
108090001092 clostripain Proteins 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
238000010954 commercial manufacturing process Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000010205 computational analysis Methods 0.000 description 1
201000004037 congenital amegakaryocytic thrombocytopenia Diseases 0.000 description 1
201000004425 congenital hypoplastic anemia Diseases 0.000 description 1
208000016598 congestive splenomegaly Diseases 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000012954 diazonium Substances 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000003721 exogen phase Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
230000009760 functional impairment Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
108060003196 globin Proteins 0.000 description 1
102000018146 globin Human genes 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
229940076085 gold Drugs 0.000 description 1
239000010931 gold Substances 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
102000055229 human IL4 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
230000014726 immortalization of host cell Effects 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000001573 invertase Substances 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
230000001589 lymphoproliferative effect Effects 0.000 description 1
230000012976 mRNA stabilization Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 1
DFTAZNAEBRBBKP-UHFFFAOYSA-N methyl 4-sulfanylbutanimidate Chemical compound COC(=N)CCCS DFTAZNAEBRBBKP-UHFFFAOYSA-N 0.000 description 1
RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
238000000465 moulding Methods 0.000 description 1
210000002894 multi-fate stem cell Anatomy 0.000 description 1
206010028537 myelofibrosis Diseases 0.000 description 1
210000004457 myocytus nodalis Anatomy 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
230000002956 necrotizing effect Effects 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000011369 optimal treatment Methods 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000002138 osteoinductive effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
238000002205 phenol-chloroform extraction Methods 0.000 description 1
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
208000007232 portal hypertension Diseases 0.000 description 1
238000010248 power generation Methods 0.000 description 1
230000001581 pretranslational effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
108010087851 prorelaxin Proteins 0.000 description 1
230000004845 protein aggregation Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
229960003581 pyridoxal Drugs 0.000 description 1
235000008164 pyridoxal Nutrition 0.000 description 1
239000011674 pyridoxal Substances 0.000 description 1
235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
229960001327 pyridoxal phosphate Drugs 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000000763 radioactive isotope labeling Methods 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
102000037983 regulatory factors Human genes 0.000 description 1
108091008025 regulatory factors Proteins 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
210000003660 reticulum Anatomy 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
238000009938 salting Methods 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
210000000717 sertoli cell Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
102000035025 signaling receptors Human genes 0.000 description 1
108091005475 signaling receptors Proteins 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000011537 solubilization buffer Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
201000009225 splenic sequestration Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000037351 starvation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000007801 sublethal irradiation Methods 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
210000003014 totipotent stem cell Anatomy 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000032258 transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000007306 turnover Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229940026385 zzip Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Vehicle Body Suspensions (AREA)
Information Transfer Systems (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

SI9420079A 1994-01-03 1994-12-28 Thrombopoietin. SI9420079A (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US17655394A	1994-01-03	1994-01-03
US18560794A	1994-01-21	1994-01-21
US08/196,689 US8357513B1 (en)	1994-01-03	1994-02-15	Nucleic acids encoding mpl ligand (thrombopoietin) and fragments thereof
US22326394A	1994-04-04	1994-04-04
US08/249,376 US8192955B1 (en)	1994-01-03	1994-05-25	Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
US34865894A	1994-12-02	1994-12-02
US08/348,657 US6660256B1 (en)	1994-01-03	1994-12-02	Porcine mpl ligand

Publications (1)

Publication Number	Publication Date
SI9420079A true SI9420079A (en)	1997-02-28

Family

ID=27569151

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9420079A SI9420079A (en)	1994-01-03	1994-12-28	Thrombopoietin.

Country Status (28)

Country	Link
EP (1)	EP0738323A1 (fr)
JP (2)	JPH09508262A (fr)
CN (1)	CN1134539C (fr)
AU (1)	AU704266B2 (fr)
BG (1)	BG63639B1 (fr)
CA (1)	CA2178482C (fr)
CZ (1)	CZ296130B6 (fr)
DK (1)	DK149194A (fr)
ES (1)	ES2114786B1 (fr)
FI (1)	FI121573B (fr)
FR (1)	FR2714670B1 (fr)
GB (1)	GB2285446B (fr)
HR (1)	HRP941020A2 (fr)
HU (1)	HUT75657A (fr)
IE (1)	IE72517B1 (fr)
IL (1)	IL112184A (fr)
IT (1)	IT1283770B1 (fr)
LU (1)	LU88573A1 (fr)
LV (1)	LV11632B (fr)
NL (1)	NL9500010A (fr)
NO (1)	NO326903B1 (fr)
NZ (1)	NZ278726A (fr)
PT (1)	PT101627B (fr)
RO (1)	RO117110B1 (fr)
SG (1)	SG47030A1 (fr)
SI (1)	SI9420079A (fr)
SK (1)	SK282265B6 (fr)
WO (1)	WO1995018858A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5733761A (en)	1991-11-05	1998-03-31	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US6270989B1 (en) *	1991-11-05	2001-08-07	Transkaryotic Therapies, Inc.	Protein production and delivery
NZ271230A (en) *	1994-02-14	1998-03-25	Zymogenetics Inc	Hematopoietic proteins, production and use
US5795569A (en) *	1994-03-31	1998-08-18	Amgen Inc.	Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
GEP20002180B (en) *	1994-03-31	2000-07-25	Amgen Inc	Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5986049A (en) *	1994-12-30	1999-11-16	Zymogenetics, Inc.	Purified thrombopoietin and method of making it
TW387940B (en) *	1995-01-17	2000-04-21	Kirin Brewery	Anti-tpo monodonal antibody
AU4658596A (en)	1995-02-03	1996-08-21	G.D. Searle & Co.	Novel c-mpl ligands
US5696250A (en) *	1995-02-15	1997-12-09	Amgen Inc.	DNA encoding megakaryocyte growth and development factor analogs
CA2209298C (fr) *	1995-02-15	2001-12-18	Amgen Inc.	Analogues de ligand mpl
US5989538A (en) *	1995-02-15	1999-11-23	Amgen Inc.	Mpl ligand analogs
TW434020B (en) *	1995-03-15	2001-05-16	Kirin Brewery	Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) *	1995-03-15	2001-05-16	Kirin Brewery	Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
ZA964382B (en) *	1995-06-06	1997-12-01	Genentech Inc	Lymphotoxin and thrombopoietin for use in the treatment of cancer.
US6083913A (en) *	1995-06-07	2000-07-04	Glaxo Wellcome Inc.	Peptides and compounds that bind to a thrombopoietin receptor
US6251864B1 (en)	1995-06-07	2001-06-26	Glaxo Group Limited	Peptides and compounds that bind to a receptor
US5869451A (en) *	1995-06-07	1999-02-09	Glaxo Group Limited	Peptides and compounds that bind to a receptor
TW497972B (en) *	1995-06-08	2002-08-11	Kirin Brewery	Stable thrombopoietin (TPO)-containing lyophilized compositions
US6066318A (en)	1995-10-05	2000-05-23	G.D. Searle & Co.	Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US6031071A (en) *	1996-01-24	2000-02-29	Biophage, Inc.	Methods of generating novel peptides
US5879673A (en) *	1996-01-25	1999-03-09	Genentech, Inc.	Administration of thrombopoietin on a single day only
US7091311B2 (en)	1996-06-07	2006-08-15	Smithkline Beecham Corporation	Peptides and compounds that bind to a receptor
KR20000029998A (ko) *	1996-08-13	2000-05-25	리스 데브라 케이.	발현벡터,세포,그리고혈소판조혈인자를제조하는방법
JP4562815B2 (ja) *	1997-05-21	2010-10-13	ジェネンテック，インコーポレイテッド	トロンボポエチンの新規な投与
US5980893A (en) *	1997-07-17	1999-11-09	Beth Israel Deaconess Medical Center, Inc.	Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
KR20000006549A (ko) *	1998-06-30	2000-01-25	윤재승	생체내혈소판증식효능이향상된신규한트롬보포이에틴유도체
US20030228666A1 (en)	1998-06-30	2003-12-11	Daewoong Pharmaceutical Co., Ltd.	Novel human thrombopoietin mutein
MEP42108A (en)	1998-10-23	2011-02-10	Kiren Amgen Inc	Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
CY2010012I2 (el) *	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
UY26317A1 (es) *	2000-08-30	2000-10-31	Alfonso Cayota Carlos Pritsch	Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
US6673580B2 (en)	2000-10-27	2004-01-06	Genentech, Inc.	Identification and modification of immunodominant epitopes in polypeptides
US7332474B2 (en)	2001-10-11	2008-02-19	Amgen Inc.	Peptides and related compounds having thrombopoietic activity
EP1452093A4 (fr)	2001-11-15	2007-08-15	Kirin Brewery	Animal chimerique
KR100467750B1 (ko) *	2001-11-29	2005-01-24	씨제이 주식회사	생체내 에리스로포이에틴 활성이 증진된 융합단백질
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
ES2781475T3 (es)	2002-09-18	2020-09-02	Janssen Pharmaceuticals Inc	Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
SG131110A1 (en)	2003-08-28	2007-04-26	Ortho Mcneil Pharm Inc	Peptides and compounds that bind to thrombopoietin receptors
US7723295B2 (en)	2003-08-28	2010-05-25	Ortho-Mcneil Pharmaceutical, Inc.	Peptides and compounds that bind to a receptor
JP2007537755A (ja) *	2004-05-18	2007-12-27	イントレクソンコーポレイション	Ｄｎａクローニングベクタープラスミドのダイナミックなベクター構築のための方法
US8143380B2 (en)	2004-07-08	2012-03-27	Amgen Inc.	Therapeutic peptides
WO2006036834A2 (fr)	2004-09-24	2006-04-06	Amgen Inc.	Molecules fc modifiees
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
WO2007102946A2 (fr)	2006-01-23	2007-09-13	Amgen Inc.	Polypeptides cristallins
WO2007098547A1 (fr) *	2006-03-01	2007-09-07	Apollo Life Sciences Limited	Molécule et chimères de cette molécule
US7981425B2 (en)	2006-06-19	2011-07-19	Amgen Inc.	Thrombopoietic compounds
WO2008011664A1 (fr)	2006-07-24	2008-01-31	The University Of Queensland	Procédé de production d'une population de cellules
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
EP2162540A2 (fr)	2007-05-22	2010-03-17	Amgen Inc.	Compositions et procédés pour produire des protéines de fusion bioactives
EP2390261A4 (fr)	2009-01-20	2012-11-14	Hanall Biopharma Co Ltd	Fragment polypeptidique de thrombopoïétine humaine modifié et son procédé de fabrication
WO2014089478A1 (fr) *	2012-12-07	2014-06-12	University Of Tennessee Research Foundation	Procédés d'analyse numérique pour troubles plaquettaires et supports lisibles par ordinateur et systèmes pour leur mise en œuvre
CA2896053A1 (fr)	2012-12-21	2014-06-26	Ocata Therapeutics, Inc.	Procedes de production de plaquettes a partir de cellules souches pluripotentes, et compositions associees
CN103555760B (zh) *	2013-10-18	2015-05-20	江苏康禾生物制药有限公司	一种重组人血小板生成素的制备方法及其制剂
US20180201645A1 (en) *	2015-12-21	2018-07-19	Brainon Inc.	Composition for improving memory, learning ability, and cognitive ability
GB201700621D0 (en)	2017-01-13	2017-03-01	Guest Ryan Dominic	Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
PE20220604A1 (es) *	2019-09-20	2022-04-25	Ractigen Therapeutics	Molecula de acido nucleico para el tratamiento de la trombocitopenia y uso de la misma
BR112022011795A2 (pt)	2019-12-20	2022-08-30	Instil Bio Uk Ltd	Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
CN118086536A (zh) *	2024-04-23	2024-05-28	佛山科学技术学院	一种通过snp标记改善黄牛血小板生成素分泌的方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5260417A (en)	1989-04-03	1993-11-09	Genetics Institute, Inc.	Megakaryocyte growth promoting activity protein
AU5355790A (en) *	1989-04-19	1990-11-16	Cetus Corporation	Multifunctional m-csf proteins and genes encoding therefor
US5223408A (en) *	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
EP0616645B1 (fr) *	1991-12-06	2001-08-22	Genentech, Inc.	Cellules transformees par des convertases prohormonales
IL139335A (en)	1994-01-03	2005-08-31	Genentech Inc	Mpl ligand polypeptides, nucleic acids encoding them, vectors and host cells comprising such nucleic acids, processes for producing such polypeptides pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating thrombocytopenia

1994
- 1994-12-21 GB GB9425831A patent/GB2285446B/en not_active Expired - Lifetime
- 1994-12-21 SG SG1996003050A patent/SG47030A1/en unknown
- 1994-12-27 HR HR08/348,658A patent/HRP941020A2/hr not_active Application Discontinuation
- 1994-12-28 RO RO96-01347A patent/RO117110B1/ro unknown
- 1994-12-28 JP JP7518499A patent/JPH09508262A/ja active Pending
- 1994-12-28 SI SI9420079A patent/SI9420079A/sl unknown
- 1994-12-28 NZ NZ278726A patent/NZ278726A/en not_active IP Right Cessation
- 1994-12-28 CA CA2178482A patent/CA2178482C/fr not_active Expired - Lifetime
- 1994-12-28 HU HU9601805A patent/HUT75657A/hu not_active Application Discontinuation
- 1994-12-28 CN CNB941947513A patent/CN1134539C/zh not_active Expired - Lifetime
- 1994-12-28 WO PCT/US1994/014553 patent/WO1995018858A1/fr not_active Ceased
- 1994-12-28 SK SK875-96A patent/SK282265B6/sk not_active IP Right Cessation
- 1994-12-28 CZ CZ0192296A patent/CZ296130B6/cs not_active IP Right Cessation
- 1994-12-28 EP EP95906653A patent/EP0738323A1/fr not_active Withdrawn
- 1994-12-28 DK DK149194A patent/DK149194A/da not_active Application Discontinuation
- 1994-12-28 AU AU15146/95A patent/AU704266B2/en not_active Expired
- 1994-12-29 IL IL11218494A patent/IL112184A/en not_active IP Right Cessation
- 1994-12-30 PT PT101627A patent/PT101627B/pt not_active IP Right Cessation
- 1994-12-30 ES ES09402681A patent/ES2114786B1/es not_active Expired - Fee Related
1995
- 1995-01-02 IT IT95TO000002A patent/IT1283770B1/it active IP Right Grant
- 1995-01-02 FR FR9500007A patent/FR2714670B1/fr not_active Expired - Lifetime
- 1995-01-03 NL NL9500010A patent/NL9500010A/nl active Search and Examination
- 1995-01-03 IE IE950002A patent/IE72517B1/en not_active IP Right Cessation
- 1995-01-03 LU LU88573A patent/LU88573A1/de unknown
1996
- 1996-07-02 BG BG100693A patent/BG63639B1/bg unknown
- 1996-07-02 FI FI962723A patent/FI121573B/fi not_active IP Right Cessation
- 1996-07-02 NO NO19962783A patent/NO326903B1/no not_active IP Right Cessation
- 1996-07-24 LV LVP-96-315A patent/LV11632B/xx unknown
1997
- 1997-03-27 JP JP9074906A patent/JPH10113186A/ja active Pending

Also Published As

Publication number	Publication date
ITTO950002A1 (it)	1996-07-02
CN1134539C (zh)	2004-01-14
LU88573A1 (de)	1995-06-01
FI962723L (fi)	1996-09-03
FR2714670B1 (fr)	1997-01-10
HU9601805D0 (en)	1996-08-28
CA2178482C (fr)	2012-01-03
JPH09508262A (ja)	1997-08-26
WO1995018858A1 (fr)	1995-07-13
JPH10113186A (ja)	1998-05-06
ITTO950002A0 (it)	1995-01-02
FI962723A0 (fi)	1996-07-02
CZ296130B6 (cs)	2006-01-11
GB9425831D0 (en)	1995-02-22
ES2114786A1 (es)	1998-06-01
NO962783D0 (no)	1996-07-02
EP0738323A1 (fr)	1996-10-23
SG47030A1 (en)	1998-03-20
NO962783L (no)	1996-09-03
DK149194A (da)	1995-07-04
AU704266B2 (en)	1999-04-15
CZ192296A3 (en)	1997-05-14
CA2178482A1 (fr)	1995-07-13
HUT75657A (en)	1997-05-28
PT101627B (pt)	1996-11-29
BG100693A (en)	1998-01-30
SK282265B6 (sk)	2001-12-03
IL112184A (en)	2004-07-25
LV11632A (lv)	1996-12-20
PT101627A (pt)	1995-11-30
CN1141061A (zh)	1997-01-22
AU1514695A (en)	1995-08-01
GB2285446A (en)	1995-07-12
FI121573B (fi)	2011-01-14
GB2285446B (en)	1999-07-28
LV11632B (en)	1997-04-20
NO326903B1 (no)	2009-03-16
RO117110B1 (ro)	2001-10-30
BG63639B1 (bg)	2002-07-31
IT1283770B1 (it)	1998-04-30
NL9500010A (nl)	1995-08-01
IE950002A1 (en)	1995-07-12
SK87596A3 (en)	1997-11-05
NZ278726A (en)	1998-06-26
FR2714670A1 (fr)	1995-07-07
IL112184A0 (en)	1995-03-15
ES2114786B1 (es)	1999-01-01
HRP941020A2 (en)	1997-04-30
IE72517B1 (en)	1997-04-23

Legal Events

Date	Code	Title	Description
2005-01-10	IF	Valid on the event date

Publication	Publication Date	Title
SI9420079A (en)	1997-02-28	Thrombopoietin.
EP1009831A2 (fr)	2000-06-21	Anticorps agonistes envers le recepteur de thrombopoietine, et utilisation therapeutique de ces anticorps
RU2245365C2 (ru)	2005-01-27	Тромбопоэтин
US5830647A (en)	1998-11-03	Hybridization and amplification of nucleic acids encoding mpl ligand
DE19500030A1 (de)	1995-07-06	Thrombopoietin
BE1009021A5 (fr)	1996-10-01	Thrombopoietine.
US8147844B1 (en)	2012-04-03	Mpl ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using mpl ligand
US8278099B1 (en)	2012-10-02	Monoclonal antibody to human thrombopoietin
KR100607613B1 (ko)	2007-03-02	트롬보포이에틴
AU749175B2 (en)	2002-06-20	Thrombopoietin
KR20040065249A (ko)	2004-07-21	트롬보포이에틴
US8241900B1 (en)	2012-08-14	mpl ligand
US6660256B1 (en)	2003-12-09	Porcine mpl ligand
AU782245B2 (en)	2005-07-14	Thrombopoietin
US8399250B1 (en)	2013-03-19	Anti-mpl ligand (thromobpoietin) antibodies
IL161813A (en)	2008-07-08	CHIMERIC POLYPEPTIDES COMPRISING A HETEROLOGOUS POLYPEPTIDE AND A FRAGMENT OF A mpl LIGAND
SA95150635B1 (ar)	2006-05-27	ثرومبوبواييتين thrombopoietin (عامل مولد للصفائح الدموية )